January 27, 2021 – Civica Rx announced its plans to build a 120,000 square-foot sterile injectable manufacturing facility in Petersburg, Virginia. The new plant represents a $124.5 million investment and will potentially create more than 180 jobs, the company says.
Building its own state-of-the-art manufacturing operation in the United States has been a part of Civica’s supply strategy since it was founded in late 2018 to address drug shortages and ensure a resilient supply of quality medicines at affordable prices for U.S. patients.
Civica is a key collaborator in the U.S. government-funded partnership with Phlow Corp, Medicines for All Institute at Virginia Commonwealth University and AMPAC Fine Chemicals, which is also located in Petersburg.
Through this partnership, Phlow executed a $354 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to manufacture essential medications from beginning to end, including starting raw ingredients, Active Pharmaceutical Ingredients (APIs) and finished dosage forms.
Civica’s role is to produce finished dosage medications in vials and syringes for patient care in Civica member hospitals and for the U.S. Strategic National Stockpile.
The Civica manufacturing plant will include disposable technology and advanced technology filling lines to produce 90 million vials and 50 million pre-filled syringes a year, steam sterilization capability, automated visual inspection and packaging lines, and controlled temperature warehousing of raw materials and finished medications. The facility will be built to accommodate future growth.
Civica has initiated facility construction and expects to begin operations within three years.